Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion

Eli Lilly & Co. has signed an AI-powered drug development deal with Insilico Medicine that could be worth up to $2.75 billion.

Under the deal, announced Sunday, Insilico is eligible for $115 million in upfront payments; other milestones could bring the value to $2.75 billion, plus tiered royalties on future sales. In return, Lilly gets the exclusive worldwide rights to develop and commercialize potential medicines.

The announcement builds on the partnership between the two companies, which have been working together since 2023. Hong Kong-listed Insilico is among the most advanced of the AI-enabled drug developers, with a suite of models ...